Core Viewpoint - The announcement by BGI Genomics on September 22 highlights a significant equity change, indicating a passive dilution of shareholding and a reduction in shares held by key stakeholders [1][2]. Group 1: Equity Change Details - BGI Genomics reported a decrease in the shareholding ratio of key stakeholders from 38.1679% to 31.3223% as of September 22, 2025, marking a change that touches upon a 5% integer multiple [1]. - The stakeholders involved in this equity change include Shenzhen BGI Technology Co., Ltd., founder Wang Jian, and Shenzhen BGI San Sheng Yuan Technology Co., Ltd. [1]. Group 2: Implications of Equity Change - The reduction in shareholding may lead to changes in the company's governance structure, potentially impacting decision-making processes [1]. - The financial implications of this equity change will require further observation of the company's subsequent financial performance [1]. Group 3: Market Reaction - On September 22, BGI Genomics' stock closed at 50.41 CNY per share, down 0.55%, with a trading volume of 356 million CNY and a total market capitalization of 21.087 billion CNY [2]. - The stock has seen a decline of 2.83% over the past seven trading days, indicating potential investor sentiment fluctuations and market expectation adjustments due to the equity change [2]. Group 4: Future Outlook - The overall impact of the equity change on the company should be analyzed from multiple perspectives, including corporate governance, shareholder relations, and market performance [3]. - Despite the recent changes, BGI Genomics, as a leading enterprise in the industry, is still recognized for its long-term development potential, which may present new opportunities following the adjustment in its equity structure [3].

Core Viewpoint - The announcement from BGI Genomics indicates that BGI Holdings and its concerted parties hold a total of 131 million shares, representing 31.3223% of the company's total equity. This change in equity ownership is a result of the company's stock issuance to specific parties and the completion of the second phase of the 2022 restricted stock incentive plan, which led to a passive dilution of the shareholding percentage for the information disclosure obligors. There are currently no clear plans or agreements to increase or decrease their equity stake in the listed company within the next 12 months [1]. Group 1 - BGI Holdings and its concerted parties collectively own 131 million shares, accounting for 31.3223% of the total equity [1] - The change in ownership percentage is due to stock issuance and the completion of the restricted stock incentive plan [1] - There are no immediate plans to alter the equity stake in the next 12 months [1]

整数倍的提示性公告 控股股东深圳华大基因科技有限公司及其一致行动人汪建先生、深圳华大三 生园科技有限公司保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏。 证券代码：300676 证券简称：华大基因 公告编号：2025-052 深圳华大基因股份有限公司 股东询价转让结果报告书暨持股 5%以上股东权益变动触及 5% 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 1、本次权益变动主体为持有深圳华大基因股份有限公司（以下简称公司或华 大基因）5%以上股份的股东深圳华大基因科技有限公司（以下简称华大控股或出 让方）及其一致行动人汪建先生、深圳华大三生园科技有限公司。本次权益变动 方式为集中竞价或大宗交易方式增减持、向特定对象发行股票和限制性股票激励 计划归属登记导致持股比例被动稀释、询价转让。本次权益变动后，华大控股及 其一致行动人拥有权益的股份占公司总股本比例由38.1679%下降至31.3223%（以 下简称本次权益变动）。 2、本次询价转让出让方为公司控股股东华大控股，本次权益变动不会导致公 司控股股东及实际控制人发生变化，不会对公司治理结 ...

信息披露义务人2：汪建 住所/通讯地址：广东省深圳市 信息披露义务人 3：深圳华大三生园科技有限公司 住所/通讯地址：深圳市大鹏新区大鹏办事处鹏飞路 7 号 权益变动性质：持股比例被动稀释、股份减少 深圳华大基因股份有限公司 简式权益变动报告书 信息披露义务人1：深圳华大基因科技有限公司 住所：深圳市盐田区盐田街道沿港社区北山道 146 号北山工业区 11 栋 8 楼 通讯地址：广东省深圳市盐田区梅沙街道云华路 9 号华大时空中心 签署日期：2025 年 9 月 22 日 | 附表：简式权益变动报告书 17 | | --- | 上市公司名称：深圳华大基因股份有限公司 股票上市地点：深圳证券交易所 股票简称：华大基因 股票代码：300676 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》（简称《证券 法》）、《上市公司收购管理办法》（简称《收购管理办法》）、《公开发行证券的公司 信息披露内容与格式准则第 15 号—权益变动报告书》（简称《准则第15号》）及相 关法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准,其履行亦不违反 信息披露义务人章程或内 ...

中国国际金融股份有限公司 关于深圳华大基因股份有限公司 股东向特定机构投资者询价转让股份的核查报告 中国国际金融股份有限公司（以下简称"中金公司""组织券商"）受深圳华大 基因股份有限公司（以下简称"华大基因""公司""上市公司"）股东深圳华大基 因科技有限公司（以下简称"华大控股""出让方"）委托，组织实施本次华大基因 股东向特定机构投资者询价转让（以下简称"本次询价转让"）。 经核查，中金公司就本次询价转让的出让方、受让方是否符合《深圳证券交易所 上市公司自律监管指引第 16 号——创业板上市公司股东询价和配售方式转让股份 （2025 年修订）》（以下简称"《指引第 16 号》"）要求，本次询价转让的询价、 转让过程与结果是否公平、公正，是否符合《指引第 16 号》的规定作出如下报告说明。 一、本次询价转让概述 （一）本次询价转让出让方 截至2025年9月12日，出让方所持公司股份的数量、比例情况如下： | 出让方名称 | 截至2025年9月12日收盘持股数量（股） | 持股比例 | | --- | --- | --- | | 深圳华大基因科技有限公司 | 141,285,593 | 33.77% | 注 ...

Group 1 - The State Administration of Foreign Exchange allows foreign investors to reinvest foreign exchange profits generated in China, facilitating capital inflow and investment [2] - Nvidia is under further investigation by the State Administration for Market Regulation for violating antitrust laws related to its acquisition of Mellanox Technologies [3] - The Ministry of Commerce opposes the U.S. request for G7 and NATO members to impose tariffs on China based on its imports of Russian oil, labeling it as unilateral bullying and economic coercion [5] Group 2 - The Financial Regulatory Bureau, People's Bank of China, and China Securities Regulatory Commission launched a financial education campaign aimed at enhancing public understanding of financial rights and services [6] - The State Council emphasizes the need for online travel platforms to strengthen personal information protection and ensure compliance with regulations to safeguard consumer rights [8] - The Beijing Market Supervision Administration is investigating the ongoing controversy surrounding the pre-made dishes of the restaurant chain Xibei [9] Group 3 - CATL's sodium-ion battery has become the first in the world to pass the new national standard certification [11] - Longxin Technology has completed the development of its first GPGPU chip, expected to be delivered within the third quarter [13] - Kanglong Chemical's subsidiary has successfully passed an FDA inspection [14] - Shandong Push's application for H-share issuance has been accepted by the China Securities Regulatory Commission [20]

Group 1 - The core point of the article is that BGI Genomics announced the preliminary transfer price of its shares at 44.10 yuan per share based on the inquiry subscription situation as of September 15, 2025 [2]

Company Announcements - Junsheng Electronics' subsidiary has recently secured a global automotive intelligence project with a total order value of approximately 15 billion yuan, expected to start mass production in 2027 [1] - Shangluo Electronics plans to acquire 88.79% of Ligon Technology for 700 million yuan, focusing on authorized distribution of storage chips and various IC products [2][3] - Xinda Zheng intends to purchase at least 51% of Jiaxin Liheng Facility Management (Shanghai) Co., Ltd., with the stock currently suspended [1] - Dingtong Technology plans to invest up to 15 million USD to establish a wholly-owned subsidiary in Vietnam for R&D and production of optical module liquid cooling products [1][3] - Kexing Pharmaceutical's shareholders are inquiring about transferring shares at an initial price of 30.88 yuan per share, which is a 28% discount compared to the closing price [4] - Zhongtai Automobile has been ordered to pay 29.5 million yuan plus overdue interest due to a court ruling, which may significantly impact its current or future performance [5] - Shoukai Co., Ltd. has seen a significant increase in shareholder numbers and some institutional shareholders have reduced their holdings [5] Investment and Contracts - Laofengxiang plans to jointly invest in establishing Laofengxiang Precision Materials Company to build a modern refining and testing laboratory [8] - Longci Technology intends to invest 210 million yuan in the second phase of its Vietnam project to localize the supply of permanent magnet ferrite raw materials [9] - Sileck has signed a 230 million yuan investment cooperation agreement for a new energy precision structural components project [10] Shareholding Changes - Jingchen Co. plans to acquire 316 million yuan for 100% of Chip Micro Semiconductor [6] - Beijing Junzheng has seen a reduction of 4.8254 million shares by its shareholder Beijing Yitang Shengxin [5] - Green Harmony's actual controllers have completed a reduction of 2.99% of their shares [7] - Hangke Technology's actual controller plans to transfer 3% of the total share capital [7] Stock Price Movements - Nanfeng Co. has reported that its 3D printing service project has not yet materialized, which may affect its current year's revenue and profit [3] Other Developments - Borui Pharmaceutical's BGM0504 tablets have been approved for clinical trials in overweight/obese adults, with no similar oral formulations approved globally [4] - Southwest Securities' subsidiary will lose its listing status on September 29 due to failure to meet resumption guidelines [20]

Group 1 - A total of 67 stocks experienced block trading on September 15, with a total transaction value of 2.22 billion yuan [1] - The top three stocks by transaction value were Hangzhou Steel (2.5 billion yuan), Guangqi Technology (2.23 billion yuan), and Demingli (2.04 billion yuan) [1] - Among the stocks, 10 were traded at par, 4 at a premium, and 53 at a discount; Zhejiang Meida, SF Holding, and HNA Technology had the highest premium rates of 9.04%, 7.06%, and 1.35% respectively [1] Group 2 - The top stocks by institutional buying were Hangzhou Steel (250 million yuan), Jiangsu Leili (198 million yuan), and Haiguang Information (106 million yuan) [2] - Other notable institutional purchases included Caida Securities (63.6 million yuan), BGI (25 million yuan), and Ningde Times (20.9 million yuan) [2] Group 3 - The top stocks by institutional selling included Xinyi Technology (21 million yuan), Ningde Times (20.9 million yuan), and BYD (20.8 million yuan) [3]

Core Points - The core viewpoint of the article is that BGI Genomics (300676) announced the preliminary transfer price of shares at 44.10 yuan per share based on the inquiry subscription situation on September 15 [1] Group 1 - BGI Genomics is conducting a non-public transfer of shares, which will not be executed through centralized bidding or block trading methods [1] - The shares acquired through the inquiry transfer cannot be transferred by the acquirer within six months after the acquisition [1]